Copyright © 2012 V. T. T. Huyen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global prevalence of diabetes: estimates for the year 2000 and projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053, 2004. View at Publisher · View at Google Scholar · View at Scopus
2. N. Winer and J. R. Sowers, “Epidemiology of diabetes,” Journal of Clinical Pharmacology, vol. 44, no. 4, pp. 397–405, 2004. View at Publisher · View at Google Scholar · View at Scopus
3. R. R. Holman, “Long-term efficacy of sulfonylureas: a United Kingdom prospective diabetes study perspective,” Metabolism, vol. 55, no. 1, pp. S2–S5, 2006. View at Publisher · View at Google Scholar · View at Scopus
4. R. C. Turner, C. A. Cull, V. Frighi, and R. R. Holman, “Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49),” Journal of the American Medical Association, vol. 281, no. 21, pp. 2005–2012, 1999. View at Publisher · View at Google Scholar · View at Scopus
5. A. Norberg, K. H. Nguyen, E. Liepinsh et al., “A novel insulin-releasing substance, phanoside, from the plant Gynostemma pentaphyllum,” Journal of Biological Chemistry, vol. 279, no. 40, pp. 41361–41367, 2004. View at Publisher · View at Google Scholar · View at Scopus
6. N. K. Hoa, Å. Norberg, R. Sillard et al., “The possible mechanisms by which phanoside stimulates insulin secretion from rat islets,” Journal of Endocrinology, vol. 192, no. 2, pp. 389–394, 2007. View at Publisher · View at Google Scholar · View at Scopus
7. S. Megalli, N. M. Davies, and B. D. Roufogalis, “Anti-hyperlipidemic and hypoglycemic effects of Gynostemma pentaphyllum in the Zucker fatty rat,” Journal of Pharmacy and Pharmaceutical Sciences, vol. 9, no. 3, pp. 281–291, 2006. View at Scopus
8. T. M. Hung, D. M. Hoang, J. C. Kim, H. S. Jang, J. S. Ahn, and B. S. Min, “Protein tyrosine phosphatase 1B inhibitory by dammaranes from Vietnamese Giao-Co-Lam tea,” Journal of Ethnopharmacology, vol. 124, no. 2, pp. 240–245, 2009. View at Publisher · View at Google Scholar · View at Scopus
9. V. T. T. Huyen, D. V. Phan, P. Thang, N. K. Hoa, and C. G. Östenson, “Antidiabetic effect of Gynostemma pentaphyllum tea in randomly assigned type 2 diabetic patients,” Hormone and Metabolic Research, vol. 42, no. 5, pp. 353–357, 2010. View at Publisher · View at Google Scholar · View at Scopus
10. Department of Material Medica, Hanoi College of Pharmacy, Textbook of Material Medica, vol. 1, 2006.
11. Department of Material Medica, Hanoi College of Pharmacy, Guideline of Material Medica Practice, vol. 1, 2006.
12. WHO, “Definition, diagnosis, and classification of diabetes mellitus and its complications,” Report of a WHO Consultation, Part 1: Diagnosis and Classification of Diabetes Mellitus, World Health Organization, Geneva, Switzerlands, 1999.
13. V. Herbert, K. S. Lau, C. W. Gottlieb, and S. J. Bleicher, “Coated charcoal immunoassay of insulin,” Journal of Clinical Endocrinology and Metabolism, vol. 25, no. 10, pp. 1375–1384, 1965. View at Scopus
14. D. R. Matthews, J. P. Hosker, and A. S. Rudenski, “Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985. View at Scopus
15. M. Hanefeld, P. Brunetti, G. H. Schernthaner, D. R. Matthews, and B. H. Charbonnel, “One-year glycemic control with a suifonyurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes,” Diabetes Care, vol. 27, no. 1, pp. 141–147, 2004. View at Publisher · View at Google Scholar · View at Scopus
16. M. Roghani and T. Baluchnejadmojarad, “Hypoglycemic and hypolipidemic effect and antioxidant activity of chronic epigallocatechin-gallate in streptozotocin-diabetic rats,” Pathophysiology, vol. 17, no. 1, pp. 55–59, 2010. View at Publisher · View at Google Scholar · View at Scopus
17. R. Nahas and M. Moher, “Complementary and alternative medicine for the treatment of type 2 diabetes,” Canadian Family Physician, vol. 55, no. 6, pp. 591–596, 2009. View at Scopus
18. H. Tsuneki, M. Ishizuka, M. Terasawa, J. B. Wu, T. Sasaoka, and I. Kimura, “Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans,” BMC Pharmacology, vol. 4, article no. 18, 2004. View at Publisher · View at Google Scholar · View at Scopus
19. M. B. Davidson and A. L. Peters, “An overview of metformin in the treatment of type 2 diabetes mellitus,” American Journal of Medicine, vol. 102, no. 1, pp. 99–110, 1997. View at Publisher · View at Google Scholar · View at Scopus
20. G. Charpentier, F. Fleury, M. Kabir, L. Vaur, and S. Halimi, “Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients,” Diabetic Medicine, vol. 18, no. 10, pp. 828–834, 2001. View at Publisher · View at Google Scholar · View at Scopus
21. H. W. Rodbard, L. Blonde, S. S. Braithwaite et al., “American association of clinical endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus,” Endocrine Practice, vol. 13, supplement 1, pp. 1–68, 2007. View at Scopus
22. J. Belsey and G. Krishnarajah, “Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis,” Diabetes, Obesity and Metabolism, vol. 10, no. 1, pp. 1–7, 2008. View at Publisher · View at Google Scholar · View at Scopus